Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | NAMPT | P43490 | 1/20 | 0.49 |
| ▸ | CNR2 | P34972 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3700457 | 1.00 | KDM4E (0.51) | KDM4EALDH1A1HSD17B10SMN1; SMN2NAMPT | |
| SCHEMBL12398 | 1.00 | KDM4E (0.51) | KDM4EALDH1A1HSD17B10SMN1; SMN2NAMPT | |
| SCHEMBL3704195 | 0.98 | NAMPT (0.50) | KDM4EALDH1A1HSD17B10SMN1; SMN2NAMPT | |
| SCHEMBL3707477 | 0.96 | NAMPT (0.49) | KDM4EALDH1A1HSD17B10SMN1; SMN2NAMPT | |
| SCHEMBL3698852 | 0.96 | ALDH1A1 (0.51) | KDM4EALDH1A1HSD17B10SMN1; SMN2NAMPT | |
| SCHEMBL3704706 | 0.93 | NAMPT (0.55) | KDM4EALDH1A1HSD17B10SMN1; SMN2NAMPT | |
| SCHEMBL3711838 | 0.91 | NAMPT (0.56) | KDM4EALDH1A1HSD17B10SMN1; SMN2NAMPT | |
| SCHEMBL2678553 | 0.87 | KDM4E (0.49) | KDM4EALDH1A1HSD17B10NAMPTCNR2 | |
| SCHEMBL13688849 | 0.84 | ALDH1A1 (0.56) | KDM4EALDH1A1HSD17B10NAMPTCNR2 | |
| SCHEMBL3987956 | 0.84 | KDM4E (0.50) | KDM4EALDH1A1HSD17B10NAMPTCNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9302989-B2 | NAMPT and rock inhibitors | ABBVIE INC. (US) | 2016-04-05 | — | — | US | disclosed |
| US-20120122842-A1 | NAMPT AND ROCK INHIBITORS | ABBOTT LABORATORIES (US) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122842-A1 | NAMPT AND ROCK INHIBITORS | NAMPT, NNMT, NME2 | KDM4E 3173/4885ALDH1A1 2689/4885HSD17B10 1849/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.